Efficacy and safety of thalidomide in patients with hepatocellular carcinoma

Table 3 Comparison of patients with partial response or stable disease with patients with progressive disease

Characteristic	PR1 + SD2	PD3	P
	n	n
Sex			1.0
Male	8	23
Female	3	8
Age			0.234
> 60 yr	10	21
≤ 60 yr	1	10
Cirrhosis			0.041a
Absent	0	11
Present	11	20
Hepatitis
Hepatitis B	4	13	1.0
Hepatitis C	3	9	1.0
TNM stage
I + II	3	4	1.0
IIIA + IIIB	4	19	0.180
IVA + IVB	4	8	1.0
Child-Pugh classification
Grade A	5	21	0.280
Grade B	6	8	0.136
Grade C	0	2	1.0
Okuda stage
I	3	8	1.0
II	8	19	0.717
III	0	4	0.558
CLIP score
0-2	7	13	0.298
3-6	4	18	0.298
α-fetoprotein			0.081
> 400 ng/mL	3	19
< 400 ng/mL	8	12
Tumor size			0.034a
≤ 5 cm	7	8
> 5 cm	4	23

¹Partial response;

²Stable disease;

³Progressive disease;

^aP < 0.05 between the two groups.